Lhotse Bio Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders, multiple sclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly nonalcoholic fatty liver disease [NAFLD]), osteoporosis, SARS-CoV-2 infection (COVID-19) and transplant rejection.